Study observes ‘trend toward efficacy’ with lanadelumab in pediatric patients with HAE
A study compared the safety and efficacy of lanadelumab versus another long-term prophylaxis treatment for hereditary angioedema (HAE) in pediatric patients and found a “trend toward greater efficacy and fewer adverse events” with lanadelumab.
The systematic literature review included 2 studies and 29 patients aged <12 years with HAE—1 assessed lanadelumab 150 mg administered every 2 weeks and the other assessed intravenous (IV) C1-esterase inhibitor 1 at 2 dose schedules.
Lanadelumab reduced the monthly AE attack rate by 82.1% compared with C1-esterase inhibitor 1,000 IU twice weekly (rate ratio [RR], 0.1792) and by 88.9% versus IV C1-esterase inhibitor 500 IU twice weekly (RR, 0.1107).
Lanadelumab also reduced the risk of total adverse events by 56.2% (RR, 0.4377) and 66.0% (RR, 0.3401), respectively, compared with the 2 IV C1-esterase inhibitor dose schedules.
The researchers noted that a larger sample size and longer assessments are needed to confirm the efficacy, safety, and tolerability of lanadelumab versus the IV C1-esterase inhibitor.
Reference
Watt M, Goldgrub R, Malmenäs M, Haeussler K. Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema. J Comp Eff Res. 2025:e240110. doi:10.57264/cer-2024-0110